)
Edge28 Aug 2026
Bigger, Sharper, IMAX: A Blockbuster Business
How IMAX turned an unscalable, large-screen format into the center of blockbuster filmmaking through cameras, projection, and remastering technology.
Fulcrum Therapeutics
Fulcrum Therapeutics (FULC) investor relations material
Fulcrum Therapeutics M&A announcement summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.M&A announcement summary17 Aug, 2026
Deal rationale and strategic fit
Merger creates a leading migraine-focused biotech company, leveraging Slate's pipeline of next-generation therapeutics and expertise to address significant unmet needs in migraine treatment.
Strategic review identified this transaction as the optimal path for stockholder value and therapeutic advancement.
Financial terms and conditions
All-stock transaction with pre-merger Fulcrum stockholders owning 5%, Slate stockholders (including new investors) owning 95%, subject to adjustment.
$245 million oversubscribed private placement led by top healthcare investors, funding operations into 2029.
Fulcrum to contribute $20.3 million net cash and pay a $270 million special cash dividend to its pre-merger stockholders before closing.
Integration plans and timeline
Slate's CEO and senior management will lead the combined company, which will be renamed and trade as Slate Medicines on Nasdaq.
Slate's board of directors will serve as the board of the combined company.
Merger expected to close in Q4 2026, subject to stockholder approval and customary conditions.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Fulcrum Therapeutics
- Discontinued lead program, restructured operations, and reviewing strategic alternatives amid ongoing losses.FULC
Q2 2026 - Pociredir Phase 1b readouts in sickle cell disease expected in 2025, with pipeline expansion underway.FULCLeerink’s Global Healthcare Conference 2025
- Director elections, executive pay, and auditor ratification headline the 2026 annual meeting.FULCProxy filing
- Stockholders will vote on director elections, executive pay, and auditor ratification.FULCProxy filing
- Pociredir demonstrated strong efficacy and safety in SCD, supporting advancement to late-stage trials.FULCCorporate presentation
- Pociredir showed strong efficacy and safety, with $333M cash runway supporting operations into 2029.FULCQ1 2026
- Pociredir achieved rapid, robust HbF increases and improved outcomes in sickle cell disease.FULC44th Annual J.P. Morgan Healthcare Conference
- Pivotal study planned after strong PIONEER data, with focus on sickle cell and U.S. launch.FULCLeerink Global Healthcare Conference 2026
- Pociredir achieved strong HbF induction and safety in SCD, advancing toward pivotal trials.FULCCorporate presentation
Next Fulcrum Therapeutics earnings date
Q3 202628 Oct, 2026
Fulcrum Therapeutics
Next Fulcrum Therapeutics earnings date
Q3 202628 Oct, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Explore our global coverage